title: Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma.
abstract: BACKGROUND
  The majority of lymphomas in the ocular adnexa are low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma). Although radiotherapy is the most frequently applied management, cataract and dry eye are problematic complications.
  
  
  METHODS
  Between 1973 and 2003, the clinical features of 36 patients with ocular adnexal MALT lymphoma with no symptoms who were managed with no initial therapy after biopsy or surgical resection were retrospectively analyzed.
  
  
  RESULTS
  The median patient age was 63 years (range 22-84) and all patients had stage I disease, consisting of 31 unilateral cases and five bilateral cases. With a median follow-up of 7.1 years, 25 (69%) did not require treatment. The median time until the initiation of treatment in the remaining 11 patients (31%) was 4.8 years. Six patients (17%) died, and among them only two (6%) died due to progressive lymphoma. Seventeen patients (47%) progressed, but histologic transformation was recognized in only one (3%). The estimated overall survival rates of the 36 patients after 5, 10 and 15 years were 94%, 94% and 71%, respectively.
  
  
  CONCLUSIONS
  In selected patients with ocular adnexal MALT lymphoma, no initial therapy might be an acceptable approach, because 70% of patients remained untreated at a median of 8.6 years, and their survival was comparable to that of reports on immediate therapy.
authors.affiliation: Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tanimoto
authors.forename: A
authors.initials: A
authors.lastname: Kaneko
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: N
authors.initials: N
authors.lastname: Sekiguchi
authors.forename: D
authors.initials: D
authors.lastname: Maruyama
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kagami
authors.forename: A
authors.initials: A
authors.lastname: Maeshima
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuno
authors.forename: K
authors.initials: K
authors.lastname: Tobinai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009918:Orbital Neoplasms / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies